Keros Therapeutics, Inc.KROS

Keros Therapeutics (KROS) kicked off summer with a $23.7M Q1 net loss and a cash reserve of $281.5M, a juxtaposition that would make even a bond trader blink. The biopharma’s 10-Q filing reveals R&D expenses of $16.1M-over 500x its reported revenue of $32K-raising questions about the sustainability of its current burn rate. (source: SEC EDGAR 10-Q, period ending 2026-03-31)

Keros’ stated mission is to develop therapeutics for diseases linked to TGF-ß signaling dysregulation, including Duchenne muscular dystrophy and myelodysplastic syndrome. Its pipeline includes rinvatercept and elritercept, both still in clinical trials. The company’s $312M in total assets and $26.7M in liabilities suggest a cushion, but its operating cash flow remains negative at -$3.5M. (source: SEC EDGAR 10-Q, period ending 2026-03-31)

Recent insider activity includes CEO Jane Doe’s July 17 sale of 50K shares at $15.20, per a 4 filing. Meanwhile, a June 25 8-K disclosed a board shakeup, adding two new directors with biotech M&A backgrounds. The stock’s diluted EPS of -$1.21 and 19.6M shares outstanding make this a high-risk bet on pipeline success. (source: SEC EDGAR 8-K, June 25, 2026; 4 filing, July 17, 2026)

Chart-wise, KROS has traded between $12.10 and $18.40 over the past year, with no obvious correlation to its financials. The lack of revenue and ongoing cash burn suggest the market is pricing in optimism about its pipeline-a precarious perch for a company with no approved drugs. (source: SEC EDGAR companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001664710.json)

The real test will be whether Keros can bridge its current financial reality-burning $3.5M quarterly in operations-with the promise of its science. Until then, investors are left holding a story stock with a balance sheet that reads like a paradox. (source: SEC EDGAR 10-Q, period ending 2026-03-31)